An analysis of past clinical trials in the development of advanced therapies for non-small cell lung cancer suggests that success can be improved if identified biomarkers or receptors are used as the targets of the drug.
Read MoreResearchers at the National Cancer Institute have launched a trial to determine whether assigning treatment based on specific gene mutations can provide benefit to patients with metastatic solid tumors.
Read More
New products include the Cytation 3 cell imaging multi-mode reader by BioTek and the myPlan Lung Cancer test from Myriad.
Read MoreClarient Diagnostic Services has modified its CLIA-certified facility in Houston, Tex, to support a full range of clinical diagnostic testing for cancer. The facility previously offered nucleic acid sequencing and genomics capabilities services.
Read More
Qiagen NV and Exosome Diagnostics Inc. have expanded their existing strategic partnership to develop a first-in-class, noninvasive molecular diagnostic for use in detecting and monitoring actionable genetic mutations in lung cancer patients.
Read More